Company Profile

ERIS LIFESCIENCES LTD.

NSE : ERISBSE : 540596ISIN CODE : INE406M01024Industry : Pharmaceuticals & DrugsHouse : Private
BSE369.200.9 (+0.24 % )
PREV CLOSE (Rs.) 368.30
OPEN PRICE (Rs.) 370.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 691
TODAY'S LOW / HIGH (Rs.)369.00 371.00
52 WK LOW / HIGH (Rs.)341.05 643.75
NSE369.95 -2.45 (-0.66 % )
PREV CLOSE(Rs.) 372.40
OPEN PRICE (Rs.) 377.70
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 369.95 (100 )
VOLUME 106759
TODAY'S LOW / HIGH(Rs.) 369.00 380.15
52 WK LOW / HIGH (Rs.)321 644

Company News

Date Heading Details
11-Mar-2020 Eris Lifesciences informs about outcome of board meeting <p align="justify">Eris Lifesciences has informed that the Board of Directors of the Company at their meeting held today, March 11, 2020 duly approved the declaration of Interim Dividend of Rs 2.87 (at the rate of 287%) on each fully paid-up equity share of Re 1 for the Financial Year 2019-20. Further informed that, the Company has fixed 20th March, 2020 as the record date to determine the names of the equity shareholders, who shall be entitled to receive the payment towards interim dividend for the financial year 2019-20. The payment of the interim dividend would be made to the eligible shareholders on or before 10th April, 2020.<p align="justify">The above information is a part of company's filings submitted to BSE.</p>
11-Mar-2020 Board declares Interim Dividend Eris Lifesciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 11, 2020 duly approved the declaration of Interim Dividend of Rs. 2.87/- (at the rate of 287%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2019-20.
11-Mar-2020 OUTCOME OF THE BOARD MEETING HELD TODAY, I.E. March 11, 2020 The Board of Directors of the Company at their meeting held today i.e. March 11, 2020 duly approved the declaration of Interim Dividend of Rs. 2.87/- (at the rate of 287%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2019-20. We further inform that, the Company has fixed 20th March, 2020 as the record date to determine the names of the equity shareholders, who shall be entitled to receive the payment towards interim dividend for the financial year 2019-20. The payment of the interim dividend would be made to the eligible shareholders on or before 10th April, 2020.
05-Mar-2020 Board Meeting Intimation for BOARD TO CONSIDER INTERIM DIVIDEND & OTHER CONNECTED MATTERS Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/03/2020 ,inter alia, to consider and approve NOTICE IS HEREBY given that a Meeting of the Board of Directors of Eris Lifesciences Limited ("the Company") is scheduled to be held on Wednesday, 11th March, 2020 to, inter alia, consider and approve the declaration of Interim Dividend on the equity shares of the Company for the Financial Year 2019-20. The Record date for the purpose of determining the Members eligible to receive Interim Dividend, if declared, by the Board of Directors, has been fixed as 20th March, 2020.
05-Mar-2020 BOARD TO CONSIDER INTERIM DIVIDEND & OTHER CONNECTED MATTERS NOTICE IS HEREBY given that a Meeting of the Board of Directors of Eris Lifesciences Limited ("the Company") is scheduled to be held on Wednesday, 11th March, 2020 to, inter alia, consider and approve the declaration of Interim Dividend on the equity shares of the Company for the Financial Year 2019-20. The Record date for the purpose of determining the Members eligible to receive Interim Dividend, if declared, by the Board of Directors, has been fixed as 20th March, 2020.
05-Mar-2020 Corporate Action-Board to consider Dividend NOTICE IS HEREBY given that a Meeting of the Board of Directors of Eris Lifesciences Limited ("the Company") is scheduled to be held on Wednesday, 11th March, 2020 to, inter alia, consider and approve the declaration of Interim Dividend on the equity shares of the Company for the Financial Year 2019-20. The Record date for the purpose of determining the Members eligible to receive Interim Dividend, if declared, by the Board of Directors, has been fixed as 20th March, 2020.
08-Feb-2020 Eris Lifesciences submits board meeting intimation <p align="justify">Eris Lifesciences has submitted the board meeting intimation.<br></p><p align="justify">The above information is a part of company's filings submitted to BSE.<br></p>
07-Feb-2020 Board Meeting Intimation for Board Meeting Intimation Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2020 ,inter alia, to consider and approve NOTICE IS HEREBY given that a Meeting of the Board of Directors of Eris Lifesciences Limited ('the Company') is scheduled to be held on Friday, 14th February, 2020 to, inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter and nine months ended 31st December, 2019. Further, as informed by us vide letter dated 26th December, 2019, the trading window has been already closed from 1st January, 2020 and will remain closed till 48 hours after the declaration of financial results of the Company pursuant to SEBI [Prohibition of Insider Trading] Regulations, 2015 and Policy on 'Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company'' for the purpose of Board Meeting.
27-Jan-2020 Eris Lifesciences informs about updates on buyback offer <p align="justify">Axis Capital (Manager to Buyback Offer) has submitted a copy of post Buyback Public Announcement for the attention of the Equity Shareholders/ Beneficial Owners of Equity Shares of Eris Lifesciences (Target Company).<p align="justify">The above information is a part of company's filings submitted to BSE.</p>
27-Jan-2020 Updates on Buyback Offer Axis Capital Limited ("Manager to Buyback Offer) has submitted to BSE a copy of post Buyback Public Announcement for the attention of the Equity Shareholders / Beneficial Owners of Equity Shares of Eris Lifesciences Ltd ("Target Company").